Acarbose is an oral medication used to treat type 2 diabetes. It helps control blood sugar levels by slowing the digestion of carbohydrates in the body. It works by blocking enzymes that break down carbohydrates into simple sugars. This reduces the amount of sugar released into the blood, which helps keep blood sugar levels within a healthy range.
Acarbose is approved for use in more than 70 countries worldwide and is available as a generic medication in some countries. It is usually taken three times a day, with meals and snacks, to help control blood sugar levels. The usual starting dose is 25mg, and the dose can be increased gradually up to 100mg per day if needed. Common side effects include flatulence, diarrhea, nausea, and abdominal pain.
The global Acarbose market was valued at US$ 138.8 million in 2022 and is anticipated to reach US$ 168.8 million by 2029, witnessing a CAGR of 2.8% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
A detailed market research report on Global Acarbose Market available at: https://www.themarketreports.com/report/global-acarbose-market-research-report
This report aims to provide a comprehensive presentation of the global market for Acarbose, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acarbose.
The key players are Bayer, CKDBioCorporation, Hangzhou East China Pharmaceutical, Livzon Pharmaceutical Group, Hebei Huarong Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhebei Pharmaceutical etc. Top 3 companies occupied about 83% market share.
Ask for more details or sample of this report at: https://www.themarketreports.com/report/ask-your-query/1387240
Release by:
Shirish Gupta
Marketing Manager
The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email:sales@themarketreports.com